Imdelltra (Tarlatamab-dlle)

 Imdelltra (tarlatamab-dlle) is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager used for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. As a bispecific T-cell engager (BiTE) antibody construct, this therapeutic drug targets the CD3 receptor on T-cells and the DLL3 protein on SCLC cells, promoting T-cell mediated cytotoxicity against DLL3-expressing tumor cells. 

Note: Imdelltra 1 mg/10 mg received accelerated approval due to its encouraging response rate and duration of response in clinical studies. Continued approval may require confirmation of clinical benefit in further trials.

Recommended Dosage: The recommended dosage of Imdelltra (tarlatamab-dlle) varies based on patient specifics and clinical protocol. Typically, it is administered as an intravenous infusion, with the initial dose followed by subsequent doses at regular intervals. Dosage adjustments may be necessary based on patient response and tolerance. Always follow the prescribing physician’s guidelines and the product’s official prescribing information for precise dosing.

• Imdelltra can cause CRS, a potentially severe inflammatory response. Symptoms include fever, fatigue, headache, and hypotension. Immediate medical intervention is crucial for severe cases. Patients should be monitored for signs of CRS, especially during the first infusion. Pre-medication with corticosteroids and antipyretics may be considered to mitigate the risk.
  
• Tarlatamab-dlle can cause neurological side effects such as headache, confusion, seizures, and encephalopathy. Regular neurological assessments should be performed, and any new or worsening symptoms should be reported immediately. In severe cases, treatment may need to be interrupted or discontinued.
  
• Due to its immunomodulatory effects, Imdelltra can increase the risk of infections, including opportunistic infections. Patients should be monitored for signs of infection, and prophylactic antibiotics or antiviral medications may be considered. Prompt treatment of infections is critical to prevent complications.
  
• Imdelltra can cause hematologic abnormalities such as neutropenia, anemia, and thrombocytopenia. Complete blood counts should be monitored regularly. Dosage adjustments or supportive treatments like growth factors and transfusions may be necessary to manage these side effects.
  
• Cardiovascular events, including arrhythmias and hypertension, have been reported with tarlatamab-dlle. Patients should undergo baseline and periodic cardiovascular assessments. Any new or worsening cardiovascular symptoms should be evaluated promptly, and treatment modifications may be required.
  
• Imdelltra can cause liver toxicity, manifested by elevated liver enzymes and bilirubin levels. Liver function tests should be performed before and during treatment. Patients with significant liver function abnormalities may require dose adjustments or discontinuation of therapy.
  
• Serious hypersensitivity reactions, including anaphylaxis, can occur with Imdelltra. Patients should be closely monitored for signs of allergic reactions during and after infusions. Emergency medications and equipment should be readily available to manage severe reactions. Discontinue treatment if a serious hypersensitivity reaction occurs.
  

What documents are required to import IMDELLTRA to India?

IMDELLTRA (tarlatamab-dlle) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

IMDELLTRA (tarlatamab-dlle injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Imdelltra in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of IMDELLTRA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for the Imdelltra injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the IMDELLTRA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Imdelltra®?

Tarlatamab-dlle is a Generic Name for the trade name drug Imdelltra®.

What is the Manufacturer’s Name of Imdelltra®?

Imdelltra® is manufactured by Amgen Inc.

Is Imdelltra® approved by the FDA?

Yes, Imdelltra® is approved by the FDA. Date of first approval: May 16, 2024.

What is the dosage and form of Imdelltra® supplied?

Imdelltra® is supplied as injections: 1 mg/10 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution for intravenous administration. 

What are the most common side effects of Imdelltra®? 

The most common side effects of Imdelltra® are cytokine release syndrome, fatigue, decreased appetite, musculoskeletal pain, pyrexia, dysgeusia, constipation, anemia, and nausea.  

How much does Imdelltra® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Imdelltra in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Imdelltra®?

Store Imdelltra® in a refrigerator at 36°F to 46°F (2°C to 8°C); protect from light and do not freeze.

Is it safe to buy Imdelltra® online in India?

Yes, one can buy Imdelltra online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Imdelltra® through legal channels.